drugset / Trial / NCT02858271

Study to Assess the Absorption, Metabolism, Excretion and Pharmacokinetics of [14C]-AKB-9778

NCT02858271

Phase 1 Completed 6 enrolled Aerpio Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

Open-label, single-dose, Phase 1 study to assess the absorption, metabolism, excretion and pharmacokinetics of \[14C\]-AKB-9778 in healthy male volunteers

Timeline

Start
2016-07
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AKB-9778 Unknown Subcutaneous

Indications

No indication recorded.